Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesImproved survival for stage IV melanoma from an unknown primary site
Journal of Clinical Oncology, 07/20/09
Lee CC et al. - The survival advantage previously reported for patients with stage III melanoma from an unknown primar (MUP) also applies to patients with stage IV MUP. The mechanism responsible for this improved survival may provide clues for more effective treatment of stage IV melanoma and therefore warrants further investigation.
Methods- Study investigates the survival benefit in MUP pts with distant (stage IV) metastasis as reported before for stage III pts
- Acquired data for 2,247 pts was reviewed prospectively
- Cox regression analysis in a multivariate model identified prognostic factors significant for survival
- MUP and MKP (melanoma from a known primary) pts were then matched by significant covariates
- Overall survival (OS) was estimated by Kaplan-Meier method and compared by log-rank analysis
- There were 1,849 MKP and 398 MUP pts
- Known/unknown primary and 5 other significant covariates: age, sex, site of metastasis, number of different metastatic sites, and decade of diagnosis were identified
- Prognostic matching yielded 392 MUP-MKP pairs
- Median OS and 5-yr OS rate were greater for MUP pts than for all matched MKP pts or for MKP pts matched by M1 category or number of metastatic sites
Related Articles
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma
American Journal of Clinical Oncology, 10/06/09
Relevance Score: 89%
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09
Relevance Score: 88%
A phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma
Journal of Clinical Oncology, 10/19/09
Relevance Score: 87%
Prognostic predictors and long-term outcome of postoperative irradiation in thymoma: A study of 241 patients
Cancer Investigation, 11/16/09
Relevance Score: 81%
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
European Journal of Cancer, 10/02/09
Relevance Score: 81%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
Human Pathology, 12/19/09
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Human Pathology, 12/19/09
Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions
Journal of Clinical Oncology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor